Methods and means for increasing resistance to cell damage
View Patent ↗Methods are provided to increase resistance to cell damage in a subject. The increase in resistance to cell damage in a subject in the subject is accomplished by decreasing activity of eEF2 kinase in the subject. The eEF2 kinase activity can be decreased by decreasing the amount of functional eEF2 kinase produced by the subject, including contacting the eEF2 kinase with a compound that inhibits phosphorylation of eEF2 kinase substrate or decreasing the amount of functional eEF2 kinase is decreased by reducing expression of a gene encoding the eEF2 kinase.
1. A method of reducing damage to a cell caused by cytotoxic agents or increasing resistance to damage to a cell caused by cytotoxic agents, comprising delivering to tissues exposed to a cytotoxic agent an amount of a compound that decreases phosphorylation of eEF2 kinase substrate by eEF2 kinase, wherein said amount is effective to reduce said cell damage.
2. The method of claim 1 , wherein said phosphorylation of said eEF2 kinase substrate is decreased by decreasing eEF2 kinase catalytic activity in said cell.
3. The method of claim 1 , wherein said phosphorylation of eEF2 kinase substrate is decreased by reducing expression of a gene encoding the eEF2 kinase in said cell.
4. The method of claim 3 , wherein said expression of a gene encoding the eEF2 kinase is reduced by contacting said gene, or an mRNA transcribed from said gene, with a compound comprising a polynucleotide selected from the group consisting of an antisense oligonucleotide, a ribozyme, an siRNA, and an shRNA.
5. The method of claim 4 , wherein said compound comprises a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2.
6. The method of claim 5 , wherein said compound comprises a nucleotide sequence complementary to a nucleotide sequence comprising the nucleotide sequence of SEQ ID NO: 1.
7. The method of claim 1 , wherein said cell damage is caused by treatment increased acidity, oxidative stress, exposure of said cell to camptothecin (CPT), exposure of said cell to doxorubicin (DOX), and exposure of said cell to taxol.